Sign In
Buy PRAX
$278.93
+20.85 (+8.08%)
At Close: Jun 03, 2026
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
01:01pm, Thursday, 11'th Apr 2024
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Praxis Precision Medicines to Participate in Upcoming April Conferences
09:00am, Friday, 05'th Apr 2024
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Tuesday, 02'nd Apr 2024
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
12:20am, Thursday, 28'th Mar 2024
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
04:01pm, Wednesday, 27'th Mar 2024
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo
Praxis (PRAX) Surges on Positive Epilepsy Study Results
11:56am, Wednesday, 27'th Mar 2024
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
01:34pm, Tuesday, 26'th Mar 2024
Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believ
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prio
Praxis Precision Medicines to Host PRAX-628 Program Update
04:01pm, Monday, 25'th Mar 2024
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Gro
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 08'th Mar 2024
Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
10:56am, Wednesday, 06'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric i
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Tuesday, 05'th Mar 2024
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.97 per share versus the Zacks Consensus Estimate of a loss of $3.15. This compares to loss of $13.04 per share a year ago.
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
07:00am, Tuesday, 05'th Mar 2024
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be complet
Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference
08:00am, Friday, 01'st Mar 2024
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 02'nd Feb 2024
BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for
